

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, 1/21, 15/63	A1	(11) International Publication Number: WO 00/55320
		(43) International Publication Date: 21 September 2000 (21.09.00)

(21) International Application Number: PCT/US00/05989
(22) International Filing Date: 8 March 2000 (08.03.00)

(30) Priority Data:
60/124,270 12 March 1999 (12.03.99) US

(71) Applicant (for all designated States except US): HUMAN
GENOME SCIENCES, INC. [US/US]; 9410 Key West
Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROSEN, Craig, A.
[US/US]; 22400 Rolling Hill Road, Laytonsville, MD
20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage
Hills Drive, Laytonsville, MD 20882 (US).

(74) Agents: WALES, Michele, M. et al.; Human Genome Sciences,
Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW,
ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ,
UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI
patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR,
NE, SN, TD, TG).

Published

With international search report.

*Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(54) Title: HUMAN PANCREAS AND PANCREATIC CANCER ASSOCIATED GENE SEQUENCES AND POLYPEPTIDES

(57) Abstract

This invention relates to newly identified pancreas or pancreatic cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "pancreatic cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such pancreatic cancer antigens for detection, prevention and treatment of disorders of the pancreas, particularly the presence of pancreatic cancer. This invention relates to the pancreatic cancer antigens as well as vectors, host cells, antibodies directed to pancreatic cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the pancreas, including pancreatic cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of pancreatic cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

<222> (1370)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (1400)

<223> n equals a,t,g, or c

<400> 171

```
gctgatacctg ggggagctgg agaaggggca gagtcagttc caggccctct gctttgtcac 60
ccagctgcag cacaatgaga tcatccccag tgrggccatg gccaaagctcc ggcagaaaaa 120
tccccgggca gtgcggcagg cggaggaggt tcggggtctg gagcatctgc acatggatgt 180
cgctgtcaac ttcagccagg gggccctgct gagcccccac ctccacaacg tgtgtgccga 240
ggccgtggat gccatctaca cccgccagga ggatgtccgg ttctggctgg agcaagggtg 300
ggacagttct gtgttcgagg ctctgcccac ggctcagag caggcggagc tgcctcgctg 360
caggcagggtg ggggaccgag ggaagccctg cgtctgccac tatggcctga gcctggcctg 420
gtacccctgc atgtcaagt actgccacag ccgcgaccgg cccacgccct acaagtgtgg 480
catccgcagc tgccagaaga gctacagctt cgacttttac gtgcccaga ggcagctgtg 540
tctctgggat gaggatccct acccaggcta ggggtgggagc aacctggcgg gtggctgctc 600
tgggccctact gctcttcacc agccactaga ggggggtggca accccacct gaggccttat 660
ttccctccct cccactccc ctggccctag agcctgggce cctctggccc catctcacat 720
gactgtgaag ggggtgtgga atggcagggg gtctcatgaa ggcaccccca ttcccacct 780
gtgccttctc tgcgggcaga gaggagaga agggctcccc agatctacac cctccctcc 840
tgcatctccc ctggagtgtt cacttgcaag ctgccaaaac atgatggcct ctggttgttc 900
tgttgaactc cttgaacgtt tagaccctaa aaggagtcta tacctggaca cccacctccc 960
cagacacaac tcccttcccc atgcacacat ctggaaggag ctggccctc agtcccttcc 1020
tactcccaa caaggggctc actatcccca aagaaggagc tgttggggac ccacgacgca 1080
gccctgtac tggattacag catattctca tctctggccc cgaggctgcc tggggggcga 1140
gtggagacct cccatcactg agacagatca cagaccacga gtgcctttcc cggacctgga 1200
cgttgccctc agagcaggca ccagctcttt cctctctag acagaaatat ttttgaagg 1260
ttctggggca gggaggagc atgaagtacg aggaaaactt gaattccaga tttttaatgc 1320
aaagtattta tcatttctac cagaaataaa cgttttaagt ttttacttgn aaaaaaaaaa 1380
aaaaaaaaaa aaaggggggn cg                                     1402
```

<210> 172

<211> 490

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (469)

<223> n equals a,t,g, or c

<220>

<221> misc feature

<222> (489)

<223> n equals a,t,g, or c

<400> 172

```
gcttccctct ggcaatggct cccttcagca cttctgettt ccaactcaat tcacacagga 60
```

<220>
<221> misc feature
<222> (1536)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1537)
<223> n equals a,t,g, or c

<220>
<221> misc feature
<222> (1551)
<223> n equals a,t,g, or c

<400> 170
gcgggcgtca actgtcggtc tcgcacgtct ctccctgagaa ctaccgagta ggtcgggcct 60
gcctgtgagc aaacgaggcc cctgagagct ccacctagtt cacaggataa aatcccacag 120
cagaactcgg agtcagcaat ggctaagccc cagggtggtg tagctcctgt attaattgtct 180
aagctgtctg tgaatgcccc tgaattttac ccttcagggtt attcttccag ttacacagaa 240
tcctatgagg atggttggtga ggattatcct actctatcag aatatgttca ggattttttg 300
aatcatctta cagagcagcc tggcagtttt gaaactgaaa ttgaacagtt tgcagagacc 360
ctgaatgggt gtgttacaac agatgatgct ttgcaagaac ttgtggaact catctatcaa 420
caggccacat ctatcccaaaa tttctcttat atgggagctc gcctgtgtaa ttacctgtcc 480
catcatctga caattagccc acagagtggc aacttccgcc aattgctact tcaaatgtgt 540
cggactgaat atgaagttaa agatcaagct gcaaaaagggg atgaagttac tcgaaaacga 600
tttcatgcat ttgtactctt tctgggagaa ctttatctta acctggagat caagggaaca 660
aatggacagg ttacaagagc agatattctt cagggttggtc ttcgagaatt gctgaatgcc 720
ctgttttcta atcctatgga tgacaattta atttgtgcag taaaattgtt aaagttgaca 780
ggatcagttt tggaagatgc ttggaaggaa aaaggaaaaga tggatatgga agaaattatt 840
cagagaattg aaaacgttgt cctagatgca aactgcagta gagatgtaaa acagatgctc 900
ttgaagcttg tagaactccg gtcaagtaac tggggcagag tccatgcaac ttcaacatat 960
agagaagcaa caccagaaaa tgatcctaac tactttatga atgaaccaac attttatata 1020
tctgatgggt ttcccttcac tgcagctgat ccagattacc aagagaaata ccaagaatta 1080
cttgaaagag aggacttttt tccagattat gaagaaaatg gaacagattt atccgggggt 1140
ggtgatccat acttggtatg tattgatgat gagatggacc cagagataga agaagcttat 1200
gaaaagtttt gtttggaaac agagcgtaag cgaaaacagt aaagttaaat ttcagcatat 1260
cagttttata aagcagttta ggtatggtga ttttagcagaa cacaagagag caagaaaatg 1320
tgtcacatct ataccaaatt raggatgttg agttatgtta ctaatgtatg caactttaat 1380
tttgtttaac actatctgcc aaaataaact ttattcccta taacttaaaa tgtgtatata 1440
tatataatag tttattatgt acagttaatt ctactgtttt ggctgcaata aaatcgattt 1500
tgaaataaat gaaatgttga aaattttaaa aaaaannnaaa aaaaactggc nggggggc 1558

<210> 171
<211> 1402
<212> DNA
<213> Homo sapiens

<220>
<221> misc feature

305 310 315 320
 Phe Tyr Thr Ser Asp Gly Val Pro Phe Thr Ala Ala Asp Pro Asp Tyr
 325 330 335
 Gln Glu Lys Tyr Gln Glu Leu Leu Glu Arg Glu Asp Phe Phe Pro Asp
 340 345 350
 Tyr Glu Glu Asn Gly Thr Asp Leu Ser Gly Ala Gly Asp Pro Tyr Leu
 355 360 365
 Asp Asp Ile Asp Asp Glu Met Asp Pro Glu Ile Glu Glu Ala Tyr Glu
 370 375 380
 Lys Phe Cys Leu Glu Ser Glu Arg Lys Arg Lys Gln
 385 390 395

<210> 630

<211> 189

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 630

Leu Ile Leu Gly Glu Leu Glu Lys Gly Gln Ser Gln Phe Gln Ala Leu
 1 5 10 15

Cys Phe Val Thr Gln Leu Gln His Asn Glu Ile Ile Pro Ser Xaa Ala
 20 25 30

Met Ala Lys Leu Arg Gln Lys Asn Pro Arg Ala Val Arg Gln Ala Glu
 35 40 45

Glu Val Arg Gly Leu Glu His Leu His Met Asp Val Ala Val Asn Phe
 50 55 60

Ser Gln Gly Ala Leu Leu Ser Pro His Leu His Asn Val Cys Ala Glu
 65 70 75 80

Ala Val Asp Ala Ile Tyr Thr Arg Gln Glu Asp Val Arg Phe Trp Leu
 85 90 95

Glu Gln Gly Val Asp Ser Ser Val Phe Glu Ala Leu Pro Lys Ala Ser
 100 105 110

Glu Gln Ala Glu Leu Pro Arg Cys Arg Gln Val Gly Asp Arg Gly Lys
115 120 125
Pro Cys Val Cys His Tyr Gly Leu Ser Leu Ala Trp Tyr Pro Cys Met
130 135 140
Leu Lys Tyr Cys His Ser Arg Asp Arg Pro Thr Pro Tyr Lys Cys Gly
145 150 155 160
Ile Arg Ser Cys Gln Lys Ser Tyr Ser Phe Asp Phe Tyr Val Pro Gln
165 170 175
Arg Gln Leu Cys Leu Trp Asp Glu Asp Pro Tyr Pro Gly
180 185

<210> 631
<211> 32
<212> PRT
<213> Homo sapiens

<400> 631
Phe Pro Leu Ala Met Ala Pro Phe Ser Thr Ser Ala Phe His Ser Asn
1 5 10 15
Ser His Arg Arg Ile Ala Arg Thr Gln Gly Val Glu Val Ala Val Ser
20 25 30

<210> 632
<211> 144
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (17)
<223> xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (31)
<223> xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- 10 (c) a polynucleotide encoding a polypeptide fragment of a polypeptide encoded by SEQ ID NO:X or a polypeptide fragment encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- 15 (d) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X;
- 20 (f) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in the related cDNA clone, which is hybridizable to SEQ ID NO:X, having biological activity;
- (g) a polynucleotide which is a variant of SEQ ID NO:X;
- 25 (h) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (i) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- (j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide
- 30

10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least
5 95% identical to a sequence selected from the group consisting of:
- (a) a polypeptide fragment of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (b) a polypeptide fragment of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone, having biological activity;
 - 10 (c) a polypeptide domain of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (d) a polypeptide epitope of SEQ ID NO:Y or of the sequence encoded by the cDNA included in the related cDNA clone;
 - (e) a full length protein of SEQ ID NO:Y or of the sequence encoded by the
15 cDNA included in the related cDNA clone;
 - (f) a variant of SEQ ID NO:Y;
 - (g) an allelic variant of SEQ ID NO:Y; or
 - (h) a species homologue of the SEQ ID NO:Y.
- 20 12. The isolated polypeptide of claim 11, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
13. An isolated antibody that binds specifically to the isolated polypeptide
25 of claim 11.
14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
- 30 15. A method of making an isolated polypeptide comprising:

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.
22. A method of identifying an activity in a biological assay, wherein the method comprises:
- 5 (a) expressing SEQ ID NO:X in a cell;
- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.
- 10 23. The product produced by the method of claim 20.

IPC 7	C12N15/11	C12N15/12	C12N15/62	C12N15/86	C12N5/10
	C07K14/47	C07K16/18	A61K31/713	C12Q1/68	G01N33/577
	G06F17/30				

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K C12Q G01N G06F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL [Online] 26 December 1999 (1999-12-26) BIRREN B. ET AL: "Homo sapiens chromosome 11, clone RP11-707D17" Database accession no. AC18997 XP002170377 nts. 20-1487</p> <p style="text-align: center;">---</p>	<p>2-4, 15-17, 21-26</p>
P,X	<p>WO 00 55320 A (HUMAN GENOME SCIENCES INC ;ROSEN CRAIG A (US); RUBEN STEVEN M (US)) 21 September 2000 (2000-09-21) SEQ ID NOs.171 and 630 page 494; claim 19</p> <p style="text-align: center;">---</p>	<p>2-4, 15-27, 29-33</p>
A	<p>WO 93 16180 A (MAX PLANCK GESELLSCHAFT ;UNI DEGLI STUDI G D ANNUNZIO C (IT)) 19 August 1993 (1993-08-19)</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

28 June 2001

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer _____

Blanco Urgoiti, B

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ANISOWICZ A ET AL: "A NOVEL PROTEASE HOMOLOG DIFFERENTIALLY EXPRESSED IN BREAST AND OVARIAN CANCER" MOLECULAR MEDICINE,US,BLACKWELL SCIENCE, CAMBRIDGE, MA, vol. 2, no. 5, 1 September 1996 (1996-09-01), pages 624-636, XP002060076 ISSN: 1076-1551</p> <p>---</p>	
A	<p>BERGSTROM DAVID E ET AL: "Regulatory Autonomy and Molecular Characterization of the Drosophila out at first Gene." GENETICS, vol. 139, no. 3, 1995, pages 1331-1346, XP001009906 ISSN: 0016-6731 cited in the application</p> <p>-----</p>	

Information on patent family members

International Application No

PCT/US 01/00899

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0055320 A	21-09-2000	AU 3395900 A	04-10-2000
		AU 3617600 A	04-10-2000
		AU 3617700 A	04-10-2000
		AU 3619400 A	04-10-2000
		AU 3619500 A	04-10-2000
		AU 3869400 A	04-10-2000
		WO 0055173 A	21-09-2000
		WO 0055350 A	21-09-2000
		WO 0055351 A	21-09-2000
		WO 0055180 A	21-09-2000
		WO 0055174 A	21-09-2000
WO 9316180 A	19-08-1993	IT 1254309 B	14-09-1995
		AU 3497893 A	03-09-1993
		CN 1076489 A	22-09-1993
		ZA 9301101 A	17-08-1994

THIS PAGE BLANK (USPTO)

~~Not a valid copy~~